NCT00989079 - A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2009

Primary Completion Date

December 11, 2009

Study Completion Date

December 11, 2009

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Ertugliflozin

Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.

DRUG

Placebo to Ertugliflozin

Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution